Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Safe Life Acquires AEDMAX.PL, Enters Polish Market
"Welcoming AEDMAX.PL into Safe Life is an honor and a privilege, and marks an important step on our expansion journey," says Jimmy Eriksson, CEO of Safe Life. "Their success to date builds on strengths in market position, team and product & service portfolio, and I see fantastic opportunities ahead when marrying those to the platform and depth of expertise we have across Safe Life. Poland is a very large and bustling market, and we are extremely pleased to have AEDMAX.PL join…
PR Newswire
07/05/2025
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved…
- Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine/nab-paclitaxel SoC -- VCN-01 was well-tolerated, with transient and reversible adverse events (AEs), meeting primary safety endpoint -- Greater differences between the treatment arms were observed in patients receiving 2 doses of...
Nasdaq GlobeNewswire
07/05/2025
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on…
Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company's product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which...
Nasdaq GlobeNewswire
07/05/2025
Oculis to Present at Upcoming May Investor Conferences
/ ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences: Bio€quity EuropeMay 12-14, 2025; Bruges, Belgium Company update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET Bank of America Healthcare ConferenceMay 13-15, 2025; Las Vegas, USA...
Nasdaq GlobeNewswire
07/05/2025
Personalized Treatment Plans Influence European Public's Willingness to Share…
The results indicate that people trust technology for key aspects of their healthcare and believe it will continue to deliver benefits. The results indicate that people trust technology for key aspects of their healthcare and believe it will continue to deliver benefits. Of those Europeans surveyed: " This growing confidence is encouraging forEurope, as it aligns with the ambition to accelerate thedigital transformation of healthcare, "said Dr.Ivo Broeders *, Consultant...
PR Newswire
07/05/2025
AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a…
GOSSELIES, Belgium and NANTES, France, May 7, 2025 /PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, announced today that the first cohort of participants has been dosed with ABO21009, a humanized anti-CD45RC monoclonal antibody, in a first-in-human Phase 1 study for the treatment of Rheumatoid Arthritis (RA). ABO21009 was designed to address the unmet…
PR Newswire
07/05/2025
The world's first: Grand Pharma's global innovative product STC3141 successfully…
A new breakthrough in critical care treatment that may fill clinical gap in sepsis treatment A new breakthrough in critical care treatment that may fill clinical gap in sepsis treatment About the clinical study: This study is a multi-center, randomized, double-blind, placebo-controlled Phase II dose-finding clinical study, to evaluate the efficacy, safety, and pharmacokinetic features of intravenous infusion of STC3141 injection in patients with sepsis. It enrolled 180 patients...
PR Newswire
07/05/2025
Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on…
th, 2025Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on...
Nasdaq GlobeNewswire
07/05/2025
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment…
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard BecherEdinburgh, UK, 7 May 2025 - Trogenix Ltd (“Trogenix”), a pioneering biotech company dedicated to developing innovative cancer therapies, today announces the appointment of Prof Nada Jabado and Prof Burkhard Becher to its Scientific Advisory Board (SAB), effective immediately. Together, these new SAB members will strengthen the Company's...
Nasdaq GlobeNewswire
07/05/2025
Dawn Health and Merck Launch Next-Generation Digital Ecosystem for Growth…
This release introduces key foundational capabilities. Future updates will expand the ecosystem with AI-powered features, including growth predictions, personalized treatment guidance, and real-time data capture through connected devices. This release introduces key foundational capabilities. Future updates will expand the ecosystem with AI-powered features, including growth predictions, personalized treatment guidance, and real-time data capture through connected devices. "At Dawn…
PR Newswire
07/05/2025
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on…
Additional late-breaking data suggests up to twice as many patients treated with IQIRVO ®achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatmentIQIRVO dual PPARα/δ activation impacts inflammation and fibrosisPPARα activation linked to fatigue improvement in primary biliary cholangitisPARIS, FRANCE, 7 May 2025Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced new data from two late-breaking...
Nasdaq GlobeNewswire
07/05/2025
ECOSEP and Tata Elxsi Announce Strategic Partnership to Transform Sports…
This innovative collaboration was initiated by Dr. Pakravan, Vice Chair of ECOSEP, and facilitated by Dr. Malliaropoulos, General Secretary. Speaking on behalf of ECOSEP, Prof. Nicola Maffulli, President, stated: "These are exciting times for how technology and medical science can be brought together to transform personalised care in sports. The long-term vision of Tata Elxsi marries with the aim of ECOSEP to develop and maintain 360° care for athletes and physically active individuals…
PR Newswire
07/05/2025
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant…
7 May 2025- Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% at constant exchange rates (CER) to DKK 38.8 billion.Sales in US Operations increased by 20% in Danish kroner (17% at CER). Sales in International Operations increased by 18%...
Nasdaq GlobeNewswire
07/05/2025
CROSSJECT provides updates on the EUA filing of ZEPIZURE®
Press ReleaseCROSSJECT provides updates on the EUA filing of ZEPIZURE®CROSSJECT and its EUROFINS CDMO partner successfully completed the aseptic filling of all ZEPIZURE® registration batches and anticipate the delivery of the last manufacturing data needed for U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) submission in June 2025.CROSSJECT started the final regulatory activities for the ZEPIZURE® dossier submission under EUA.CROSSJECT began manufacturing...
Nasdaq GlobeNewswire
07/05/2025
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate…
Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmedSaint-Herblain (France), May 7, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its...
Nasdaq GlobeNewswire
07/05/2025
BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway…
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens.Results from this landmark study expected to inform therapeutic strategies beyond ARDS, positioning rhu-pGSN as a promising intervention across a spectrum of acute and chronic inflammatory diseases.NORTH BRUNSWICK, N.J., May06, 2025(GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront...
Nasdaq GlobeNewswire
07/05/2025
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research…
As demonstrated in this joint research, AJICAP® can be applied to the creation of conjugates of various bioactive molecules and antibodies. The resulting antibody-bioactive substance conjugates are expected to contribute to overcoming challenges such as improving the efficacy, stability, and safety of antibody drugs that have been apparent until now. Furthermore, the results of this joint research demonstrate the potential for AJICAP® to be applied not only to ADCs but also to various…
PR Newswire
07/05/2025
YUTIQ Sees Continued Market Growth in Treatment of Chronic Non-Infectious…
Alimera Sciences/EyePoint Pharma's YUTIQ (fluocinolone acetonide) Overview Alimera Sciences/EyePoint Pharma's YUTIQ (fluocinolone acetonide) Overview YUTIQ is a sterile, non-biodegradable intravitreal implant containing 0.18 mg of fluocinolone acetonide (FA). It provides a sustained drug release at an initial rate of 0.25 µg per day over 36 months. This corticosteroid-based therapy is indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye...
PR Newswire
06/05/2025
Cellectis to Report First Quarter Financial Results on May 12, 2025
The press release will be available in the Investors section of Cellectis' website:https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions atinvestors@cellectis.com About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an...
Nasdaq GlobeNewswire
06/05/2025
Information regarding the total number of voting rights and total number of…
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025 (Article 223-16 of the General Regulations of theAutorité des Marchés Financiers )Market : NYSE Euronext ParisISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights04/30/2025 136,948,872 Total gross of voting rights: 136,948,872 Total net* of voting rights: 136,762,549 *...
Nasdaq GlobeNewswire
06/05/2025
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates…
"In the first quarter of 2025, our focus on commercial execution resulted in total revenues of $898 million, led by the strong performance of Xywav and Epidiolex. In addition, our team continues to receive positive feedback from healthcare providers on the launch of Ziihera® in its first approved indication of 2L HER2+ BTC. We are affirming our 2025 total revenue guidance range of $4.15 - $4.40 billion, reflecting our confidence in our commercial portfolio delivering top-line growth…
PR Newswire
06/05/2025
Global Medical Imaging Market Projected to Reach $82.6 Billion by 2029…
The research report provides a comprehensive analysis of the medical imaging market. It covers various product types, including X-ray systems, ultrasound devices, MRI, CT, nuclear imaging, and others like optical and photoacoustic imaging. The report evaluates leading companies, industry drivers, regional dynamics, and current trends. It also discusses emerging technologies, recent innovations in medical imaging instruments and the role of ESG in the industry. The research report provides a...
PR Newswire
06/05/2025
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is eligible for an additional 180 calendar...
Nasdaq GlobeNewswire
06/05/2025
EssilorLuxottica: Disclosure of transactions in own shares
Disclosure of transactions in own shares Paris, France (May 6, 2025 - 6:00 pm)– In accordance with the authorization granted by the Annual Shareholders' Meeting on April 30, 2024, EssilorLuxottica declares that on April 29, 2025, the following share buybacks were carried out: Name of the issuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase...
Nasdaq GlobeNewswire
06/05/2025
Altri Comunicati
